Health Care • Biotechnology: Commercial Physical & Biological Resarch
$211.36 ▼ -4.12
(-1.91%)
MKT CAP: $16.50B • VOL: 2.58M
52W L $67 52W H $219
ICLR // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $8.25B | $8.19B | $8.05B |
| YoY Revenue Growth % | +0.8% | +1.7% | — |
| Gross Profit | — | $2.34B | — |
| Gross Margin % | — | 28.6% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $442.8M | $1.03B | $904.7M |
| Operating Margin % | 5.4% | 12.6% | 11.2% |
| Net Income (GAAP) | $229.3M | $739.1M | $554.2M |
| EBITDA (Normalized) | $582.2M | $1.17B | $1.19B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $1.04B | $1.29B | $1.16B |
| Capital Expenditures (CapEx) | $174.2M | $168.1M | $362.5M |
| Free Cash Flow (FCF) | $862.0M | $1.12B | $798.6M |
| FCF Margin % | 10.4% | 13.7% | 9.9% |
| Return on Invested Capital (ROIC %) | 3.1% | 6.6% | 12.2% |
| Cash & Short-Term Equivalents | $647.3M | $538.8M | — |
| Total Debt (Short + Long Term) | $2.87B | $3.40B | $2.26B |
| Total Stockholders' Equity | $9.19B | $9.44B | $4.64B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ICLR.